Weekly Marketing Briefing: Keytruda

Week ending August 26, 2026

1. How AI is currently framing the brand

AI answers frame Keytruda in a predominantly clinical, cautious, and comparison-oriented way. Brand questions repeatedly describe Keytruda as a biologic anti–PD-1 immunotherapy, while emphasizing that substitution, treatment choice, and comparative effectiveness depend on indication, biomarkers, approvals, local rules, and insurance. The high volume of hedging/disclaimer language—58 instances, up 8 week over week—reinforces an informative but less decisive tone. Answers also contain 23 overclaim-language hits, up from 15, including “best,” “stronger,” and “superior.”

2. Share of voice vs. named competitors

The structured competitor_mentions field reports zero competitor mentions, unchanged week over week, so there is no measured competitor gaining ground. However, this result should be validated: the response excerpts themselves visibly refer to Opdivo in questions such as “how does it compare to other PD-1 drugs like Opdivo?” and “Keytruda versus Opdivo,” and to Tecentriq in the treatment-choice question. This suggests either that competitor tagging is not capturing mentions reliably or that the field is counting only a narrower definition of competitor reference.

The highest share-of-voice risk is therefore concentrated in comparison journeys:

• Generic/biosimilar and substitution questions
• Keytruda versus Opdivo positioning and effectiveness
• Keytruda versus Tecentriq treatment-choice discussions

3. Messaging consistency and content gaps

Biosimilar and substitution framing is broad but not sufficiently definitive. Across the substitution and generic questions, answers repeatedly say substitution “can happen,” “depends,” or is “not always allowed,” with regional, formulary, and prescription rules doing most of the explanatory work. Commission a clearly jurisdiction-specific, medically reviewed explainer distinguishing generic, biosimilar, interchangeability, and pharmacy substitution, with an approval-status update process.

Competitive differentiation remains largely contextual rather than brand-owned. AI consistently says Keytruda and Opdivo are not interchangeable because of differences in approved indications, dosing, combinations, biomarkers, and line of therapy. This is useful but generic. Build structured comparison content organized by cancer type and treatment setting, using label- and evidence-based distinctions without universal superiority claims.

Administration guidance is uneven. Most answers identify a 30-minute IV infusion, but only 2 of 7 mention hypersensitivity/allergic-reaction considerations. The inconsistency flag also shows allergic-reaction language omitted in 5 of 7 responses. A concise administration resource should consistently cover infusion duration, preparation, rate, monitoring, and reaction-management language.

Eligibility content risks over-broad interpretation. Responses frequently discuss transplant history, autoimmune disease, inflammatory bowel disease, pregnancy, and infection risk, but the distinction between a true contraindication and a situation requiring specialist assessment is not always crisp. Create an eligibility-and-safety hub with explicit “contraindication vs caution” framing.

4. Overclaim / compliance-adjacent language watch

Reviewers should be aware that AI-generated answers currently circulate language including “best,” “most effective,” “stronger,” “strongest,” “superior,” and “leading.” These appeared 23 times this week, particularly in Keytruda-versus-Opdivo responses. The answers generally qualify or reject universal superiority claims, but the terminology remains a compliance-adjacent monitoring issue.

5. Recommended actions

1. Audit competitor tagging immediately, using the Opdivo and Tecentriq excerpts as test cases; do not treat zero share of voice as definitive until reconciled.
2. Commission a biosimilar/substitution explainer addressing the exact pharmacy question and regional variability.
3. Build cancer-setting comparison pages for Keytruda vs Opdivo and Keytruda vs Tecentriq, centered on indication, biomarker, regimen, and evidence context.
4. Create a standardized administration FAQ to reduce omission of hypersensitivity and preparation details.
5. Publish a medically reviewed eligibility framework separating hard contraindications from high-risk, case-by-case situations.